Atossa Genetics Inc (NASDAQ:ATOS)’s share price fell 6.7% during trading on Monday . The company traded as low as $2.70 and last traded at $2.78. 527,279 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 2,816,989 shares. The stock had previously closed at $2.98.
A number of brokerages have commented on ATOS. Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of Atossa Genetics in a research note on Wednesday, January 9th. ValuEngine downgraded shares of Atossa Genetics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th.
The company has a market capitalization of $26.50 million, a P/E ratio of -0.51 and a beta of 3.82.
COPYRIGHT VIOLATION WARNING: “Atossa Genetics (ATOS) Stock Price Down 6.7%” was originally reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.wkrb13.com/2019/04/16/atossa-genetics-atos-stock-price-down-6-7.html.
About Atossa Genetics (NASDAQ:ATOS)
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Further Reading: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.